{"pub": "telegraph", "url": "https://telegraph.co.uk/business/2019/10/21/glaxo-set-800m-windfall-travel-vaccines-sale", "downloaded_at": "2019-10-21 11:30:12.631204+00:00", "title": "Glaxo set for \u00a3800m windfall from travel vaccines sale", "language": "en", "text": "GlaxoSmithKline is set to rake in more than \u00a3800m from the sale of two travel vaccines to Danish biotechnology firm Bavarian Nordic.\n\nOffloading rabies drug Rabipur and Encepur, a vaccine for viral infection tick-borne encephalitis, will give the FTSE 100 drugmaker an upfront payment of \u20ac301m (\u00a3254m) and as much as \u20ac495m in additional payments if the drugs meet certain targets.\n\nThe remainder will come from the sale of inventory over the duration of the supply arrangement.\n\nChief executive Emma Walmsley has been pushing to simplify GSK\u2019s business by spinning off and selling divisions since taking the reins in 2017.\n\nShe has scrapped predecessor Andrew Witty\u2019s diversified model with and is working...", "description": "GlaxoSmithKline is set to rake in more than \u00a3800m from the sale of two travel vaccines to Danish biotechnology firm Bavarian Nordic.", "authors": ["Hannah Uttley", "Tom Stevenson", "Roger Bootle"], "top_image": "https://www.telegraph.co.uk/content/dam/business/2017/04/01/TELEMMGLPICT000109112713-xlarge_trans_NvBQzQNjv4BquiIXdENAMkKn7_B615YUB_hpgzHKH2VxzCKwxOy96Sc.jpeg?imwidth=1200", "published_at": "2019-10-21"}